Synthesis and antileishmanial activities of novel 3-substituted quinolines

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1076-1080

  Tempone, André Gustavo ^a,b   Melo Pompeu Da Silva, Ana Cláudia ^b   Brandt, Carlos Alberto ^c   Scalzaretto Martinez, Fernanda ^b   Borborema, Samanta Etel Treiger ^b   Barata Da Silveira, Maria Amélia ^b   Franco De Andrade Jr , Heitor ^b  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (3 PHENYLPROP 2 ENYL)QUINOLIN 4 OL; 3 ALLYL 2 METHYLQUINOLIN 4 OL; 3 ALLYL 4 CHLORO 2 METHYLQUINOLINE; 4 CHLORO 2 METHYL 3 (3 PHENYLPROP 2 ENYL)QUINOLINE; ANTILEISHMANIAL AGENT; ANTIMONY; PENTAMIDINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; IC 50; LEISHMANIA CHAGASI; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA; MICE; NITRIC OXIDE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14744267865     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1076-1080.2005     Document Type: Article

References (30)

1. Amougay, A., O. Letsch, and J. P. Pete. 1996. Photorearrangement of N-alkanoyl β-enaminones. Application to the synthesis of α-amino-β,-γ-unsaturated acid derivatives. Tetrahedron 52:2405-2420.
2. Antonioletti, R., F. Bonadies, L. R. Orelli, and A. Scettri. 1992. Selective C-alkylation of 1,3-dicarbonyl compounds. Gazz. Chim. Ital. 122:237-238.
3. Balaña-Fouce, R., R. M. Reguera, C. Cubría, and D. Ordóñez. 1998. The pharmacology of leishmaniasis. Gen. Pharmacol. 30:435-443.
4. Balaraman, S., P. Tewary, V. K. Singh, and R. Madhubala. 2004. Leishmania donovani induces interferon regulatory factor in murine macrophages: a host defense response. Biochem. Biophys. Res. Commun. 30:639-647.
5. Basco, L. K., O. Dechy-Cabaret, M. Ndounga, F. S. Meche, A. Robert, and B. Meunier. 2001. In vitro activities of DU-1102, a new trioxaquine derivative, against Plasmodium falciparum isolates. Antimicrob. Agents Chemother. 45:1886-1888.
6. Berman, J. D., and J. V. Gallalee. 1985. Semiautomated assessment of in vitro activity of potential antileishmanial drugs. Antimicrob. Agents Chemother. 28:723-726.
7. Brandt, C. A., H. M. C. Ferraz, E. O. Oliveira, and M. E. Payret-Arrua. 1995. A new and efficient approach to cyclic β-enamino esters and β-enamino ketones by iodine-promote cyclization. J. Org. Chem. 60:7357-7359.
8. Croft, S. L., D. Snowdon, and V. Yardley. 1996. The activities of four anti-cancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1041-1047.
9. Davies, C. R., P. Kaye, S. L. Croft, and S. Sundar. 2003. Leishmaniasis: new approaches to disease control. Br. Med. J. 15:377-382.
10. Desjeux, P. 1992. Human leishmaniasis: epidemiology and public health aspects. World Health Stat. Q. 45:267-275.
11. Dietze, R, S. F. Carvalho, L. C. Valli, J. Berman, T. Brewer, W. Milhous, J. Sanchez, B. Schuster, and M. Grogl. 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65:685-689.
12. Duarte, M. I., O. N. Mariano, C. F. Takakura, D. Everson, and C. E. Corbett. 1992. A fast method for processing biologic material for electron microscopic diagnosis in infectious disease. Ultrastruct. Pathol. 16:475-482.
13. Fournet, A., M. E. Ferreira, A. De Arias Rojas, S. de Ortiz Torres, S. Fuentes, H. Nakayama, A. Schinini, and R. Hocquemiller. 1996. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. 40:2447-2451.
14. Garnier T., and S. L. Croft. 2002. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs 3:538-544.
15. Hauser, C. R., and G. A. Reynolds. 1948. Reactions of β-keto esters with aromatic amines. Synthesis of 2-and-4-hydroxyquinoline derivatives. J. Am. Chem. Soc. 70:2402-2404.
16. Holtzclaw, H. F., J. P. Collman, and R. M. Alire. 1958. Synthesis and infrared spectra of α,β-unsaturated-β-ketoamines and their copper chelates. J. Am. Chem. Soc. 80:1100-1102.
17. Luque-Ortega J. R., O. M. Rivero-Lezcano, S. L. Croft, and L. Rivas. 2001. In vivo monitoring of intracellular ATP levels in Leishmania donovani promastigotes as a rapid method to screen drugs targeting bioenergetic metabolism. Antimicrob. Agents Chemother. 45:1121-1125.
18. Mauel, J., and A. Ransijn. 1997. Leishmania spp. mechanisms of toxicity of nitrogen oxidation products. Exp. Parasitol. 87:98-111.
19. Panaro, M. A., A. Acquafredda, S. Lisi, D. D. Lofrumento, T. Trotta, R. Satalino, M. Saccia, V. Mitolo, and O. Brandonisio. 1999. Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-gamma and bacterial lipopolysaccharide. Int. J. Clin. Lab. Res. 29:122-127.
20. Pecoul, B., P. Chirac, P. Trouller, and J. Pinel. 1999. Access to essential drugs in poor countries: a lost battle? JAMA 281:361-367.
21. Rabinovitch, M., and S. C. Alfieri. 1987. From lysosomes to cells, from cells to Leishmania: amino acid esters as potential chemotherapeutic agents. Braz. J. Med. Biol. Res. 20:665-674.
22. Romero, G. A., M. Flores, R. M. Noronha, and E. F. Macedo. 2003. High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls. Mem. Inst. Oswaldo Cruz 98:145-149.
23. Sahu, N. P., C. Pal, N. B. Mandal, S. Banerjee, M. Raha, A. P. Kundu, A. Basu, M. Ghosh, K. Roy, and M. Bandyopadhyay. 2002. Synthesis of a novel quinoline derivative, 2-(2-methylquinolin-4-ylamino)-N-pnenylacetamide-a potential antileishmanial agent. Bioorg. Med. Chem. 10:1687-1693.
24. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight-day method for screening compounds against Leishmania donovani in golden hamsters. J. Protozool. 5:269-273.
25. Tada, H., O. Shiho, K. Kuroshima, M. Koyama, and M. Tsukamoto. 1986. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93:157-165.
26. Tempone A. G., D. Perez, S. Rath, A. L. Vilarinho, R. A. Mortara, and H. F. Jr. Andrade. 2004. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J. Antimicrob. Chemother. 54:60-68.
27. Tempone, A. G., H. F. Jr. Andrade, P. J. Spencer, C. O. Lourenc̃o, J. R. Rogero, and N. Nascimento. 2001. Bothrops moojeni venom kills Leishmania spp. with hydrogen peroxide generated by its L-amino acid oxidase. Biochem. Biophys. Res. Commun. 26:620-624.
28. Trouiller, P., E. Torreele, P. Olliaro, N. White, S. Foster, D. Wirth, and B. Pécoul. 2001. Drugs for neglected diseases: a failure of the market and public health failure? Trop. Med. Int. Health. 6:945-951.
29. Vianna, G. O. 1912. Tratamento da Leishmaniose tegumentar por injeções intravenosas de tártaro emético. An. 7° Congr. Bras. Med. Cirurg. 4:426-428.
30. Yeates, C. 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs 3:1446-1452.